The 11th World Stroke Congress highlights the high impact of stroke in low- and middle-income countries, with over 80% of global stroke burden concentrated in these regions. Experts discuss prevention and treatment strategies to reduce premature mortality from stroke by one-third by 2030.
A study suggests that heart patients should interrupt sedentary time every 20 minutes with a 7 minute bout of light physical activity to expend 770 kcal, associated with a lower risk of premature death. Regular physical activity is key to achieving a healthy life.
Combining a targeted drug with hormone therapy substantially extends survival for women with advanced breast cancer. The combination treatment lived seven months longer than hormone treatment alone, with benefits strongest in women who had previously responded to hormone therapy.
A combination of immunotherapy and chemotherapy significantly extends survival by up to ten months in patients with triple-negative breast cancer. The treatment reduces the risk of death or cancer progression by up to 40 per cent, offering new hope for young women affected by this aggressive form of breast cancer.
Researchers have assembled the largest sets of African genomic data, creating a resource to study genetic structure, disease, and protein function. They identified 10 new associations specific to African populations, including links between genetic variants and diseases such as alpha thalassemia and diabetes.
Researchers created complex origami structures with unprecedented strength, light weight, and expandability using Digital Light Processing (DLP) 3D printing. The innovative approach enables folding and refolding of the structures without breaking, paving the way for numerous potential applications.
A Phase III clinical trial shows that combining immunotherapy with chemotherapy improves progression-free and overall survival for patients with triple-negative breast cancer. The study's results establish a new standard of care in PD-L1+ patients and provide hope for those diagnosed with this aggressive form of breast cancer.
Researchers developed a polygenic risk score for lifespan based on weighted contributions from relevant genetic variants, predicting which participants were likely to live longest. They also found associations between genetic variants and Alzheimer's disease, heart disease, and smoking-related conditions with overall lifespan.
A large study found that drugs approved for women's breast cancer are also effective and well-tolerated in men. Men with metastatic breast cancer received similar treatments to women, including hormonal therapy and chemotherapy, with similar outcomes.
Atezolizumab, an antibody targeting PD-L1, improved survival in metastatic triple negative breast cancer patients by 20%, particularly those with PD-L1 positive tumors. The combination therapy also reduced disease worsening and death risk by 38% in PD-L1 positive subgroup
A phase 3 clinical trial found that ixekizumab significantly improves AS symptoms, disease activity and quality of life after 16 weeks. The treatment was well-tolerated despite more frequent adverse events compared to placebo.
The PALOMA-3 study found that the CDK4/6 inhibitor palbociclib significantly improves progression-free survival in patients with HR+/HER2- advanced breast cancer. In a new analysis, palbociclib plus fulvestrant was shown to improve overall survival by 6.9 months compared to placebo plus fulvestrant.
A bioelectronic medicine device has been shown to significantly reduce pain and fatigue in patients with lupus. The study built on previous research and used an external stimulation device to pulse through the ear, resulting in a decrease in symptoms in participants who received real stimulation.
A study highlights the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and paediatric early phase clinical trials. The legal minimum age limit in Europe is 18 years, preventing young patients from participating in trials designed for their tumor type.